Companies › Inovio Pharmaceuticals
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| INO-5401 DNA plasmid encoding WT1, PSMA, and hTERT tumor-associated antigens | WT1, PSMA, HGNC | Phase 1 | Glioblastoma | Dec 2027 |
| INO-9012 DNA plasmid encoding human interleukin-12 (IL-12) | IL12 | Phase 1 | Glioblastoma | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03491683 | INO-5401 | Phase 1 | Glioblastoma | Oncology | Dec 2027 |
| NCT03491683 | INO-9012 | Phase 1 | Glioblastoma | Oncology | Dec 2027 |
Cash and short-term investments of $37m on 2026-06-30; operating cash outflow about $80m a year; runway about 6 months at that burn, to Dec 2026
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.